DE29724281U1 - 4-Phenylpiperidin-Verbindungen - Google Patents

4-Phenylpiperidin-Verbindungen

Info

Publication number
DE29724281U1
DE29724281U1 DE29724281U DE29724281U DE29724281U1 DE 29724281 U1 DE29724281 U1 DE 29724281U1 DE 29724281 U DE29724281 U DE 29724281U DE 29724281 U DE29724281 U DE 29724281U DE 29724281 U1 DE29724281 U1 DE 29724281U1
Authority
DE
Germany
Prior art keywords
alkyl
compound
alkoxy
purity
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE29724281U
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Application filed by Synthon BV filed Critical Synthon BV
Priority to PCT/NL1997/000328 priority Critical patent/WO1998056787A1/de
Priority to US08/872,023 priority patent/US5874447A/en
Publication of DE29724281U1 publication Critical patent/DE29724281U1/de
Anticipated expiration legal-status Critical
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26647319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE29724281(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms

Description

Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt
Der Beschreibungstext wurde nicht elektronisch erfaßt

Claims (11)

1. Verbindung gemäß der Strukturformel I
sowie deren pharmazeutisch verträgliche Salze, wobei:
  • - R für eine Alkyl- oder Alkinylgruppe mit 1-4 Kohlenstoffatomen, oder eine Phenylgruppe, ggf. substituiert durch C1-4-Alkyl, Alkylthio, Alkoxy, Halogen, Nitro, Alkylamino, Methylsulfonyl oder Methylendioxy steht oder für Tetra­ hydronaphthyl steht,
  • - R1 für Wasserstoff, Trifluoro-(C1-4)-Alkyl, Alkyl oder Alkinyl steht,
  • - X für Wasserstoff, Alkyl mit 1-4 Kohlenstoffatomen, Alkoxy, Trifluoroalkyl, Hydroxy, Halogen, Methylthio oder Aralkoxy steht,
  • - R2 für folgendes steht:
  • - eine C1-C10-Alkylgruppe,
  • - eine Phenylgruppe, ggf. substituiert durch mindestens eine der folgenden Gruppen:
  • - eine C1-C10-Alkylgruppe,
  • - eine Halogengruppe,
  • - eine Nitrogruppe,
  • - eine Hydroxygruppe,
  • - und/oder eine Alkoxygruppe.
2. Verbindung gemäß Anspruch 1, wobei die R-Gruppe die 3,4-Methylendioxyphenyl­ gruppe der Strukturformel
3. Verbindung gemäß Anspruch 1 oder 2, wobei die X-Gruppe bevorzugt eine Fluor­ gruppe in 4-Position des Phenylrings ist.
4. Verbindung gemäß einem der Ansprüche 1-3, wobei die R2-Gruppe eine C1-C4- Alkylgruppe ist.
5. Verbindung gemäß einem der Ansprüche 1-4, wobei die R2-Gruppe eine C1-C2- Alkylgruppe ist.
6. Verbindung gemäß einem der vorstehenden Ansprüche, mit einer Löslichkeit bei ca. 20°C von mindestens ca. 10 mg pro ml Wasser.
7. Verbindung gemäß Anspruch 6, mit einer Löslichkeit in Wasser von mindestens 100, vorzugsweise mindestens 500 und meist bevorzugt mindestens 1000 mg pro ml.
8. Arzneimittel umfassend eine Verbindung gemäß einem der Ansprüche 1-7, sowie pharmazeutisch verträgliche Trägerstoffe/Füllstoffe.
9. Paroxetinmaleat mit einer Reinheit von mindestens 98%.
10. Paroxetinacetat mit einer Reinheit von wenigstens 98%.
11. Freie Base des Paroxetins mit einer Reinheit von mindestens 98%.
DE29724281U 1997-06-10 1997-06-10 4-Phenylpiperidin-Verbindungen Expired - Lifetime DE29724281U1 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/NL1997/000328 WO1998056787A1 (de) 1997-06-10 1997-06-10 4-Phenylpiperidin-Derivate
US08/872,023 US5874447A (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds for treating depression

Publications (1)

Publication Number Publication Date
DE29724281U1 true DE29724281U1 (de) 2000-08-10

Family

ID=26647319

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69704679T Expired - Lifetime DE69704679T2 (de) 1997-06-10 1997-06-10 4-phenylpiperidin-derivate
DE29724281U Expired - Lifetime DE29724281U1 (de) 1997-06-10 1997-06-10 4-Phenylpiperidin-Verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69704679T Expired - Lifetime DE69704679T2 (de) 1997-06-10 1997-06-10 4-phenylpiperidin-derivate

Country Status (26)

Country Link
US (4) US5874447A (de)
EP (2) EP0994872B9 (de)
JP (1) JP2002503248A (de)
KR (1) KR100543614B1 (de)
AT (1) AT200781T (de)
AU (1) AU3108097A (de)
BG (1) BG64315B1 (de)
BR (1) BR9714787A (de)
CA (1) CA2293247C (de)
CZ (1) CZ295301B6 (de)
DE (2) DE69704679T2 (de)
DK (1) DK0994872T3 (de)
EE (2) EE200200633A (de)
ES (1) ES2155995T3 (de)
GR (1) GR3035784T3 (de)
HK (1) HK1027352A1 (de)
HU (1) HU0003141A3 (de)
IL (1) IL133366A (de)
IS (2) IS1927B (de)
NO (3) NO317371B1 (de)
PL (1) PL188450B1 (de)
PT (1) PT994872E (de)
SI (1) SI0994872T1 (de)
SK (1) SK283394B6 (de)
TR (2) TR199903025T2 (de)
WO (1) WO1998056787A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
TR200002939T2 (tr) * 1998-04-09 2001-02-21 Smithkline Beecham Plc Paroksetin maleat
US20010023252A1 (en) * 1998-07-02 2001-09-20 Smithkline Beecham Plc Novel compound
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
AU724845B3 (en) * 1998-07-02 2000-09-28 Smithkline Beecham Plc Novel compound
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
WO2000008016A1 (en) * 1998-08-08 2000-02-17 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9828781D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828779D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828780D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
JP2003503493A (ja) * 1999-07-01 2003-01-28 イタルファルマコ ソシエタ ペル アチオニ パロキセチンとシクロデキストリンまたはシクロデキストリン誘導体との錯体
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
DE60007782T2 (de) * 2000-05-12 2004-12-09 Synthon B.V. Piperidinverbindungen und verfahren zu deren herstellung
AU4628000A (en) * 2000-05-12 2001-11-20 Synthon Bv Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-carbinols
HU0303827A2 (hu) * 2000-08-28 2004-04-28 Synthon B.V. Paroxetinkészítmények és eljárások ezek előállítására
JPWO2002022609A1 (ja) * 2000-09-14 2004-01-22 旭硝子株式会社 実質的に有機溶媒を含まないパロキセチン塩類の製造方法
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
WO2002085360A1 (en) * 2001-04-25 2002-10-31 Pentech Pharmaceuticals, Inc. Optimized procedures for the manufacture of paroxetine salts
US6930186B2 (en) 2001-06-13 2005-08-16 Teva Pharmacetical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
IL159280D0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
WO2003020717A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2003082804A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
EP1791531A1 (de) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetinformulierungen
AU2006275595B2 (en) * 2005-07-29 2012-08-16 Concert Pharmaceuticals Inc. Novel benzo [d] [1,3]-dioxol derivatives
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
EP2200997B9 (de) * 2007-09-13 2016-01-13 Concert Pharmaceuticals Inc. Synthese deuterierter Benzodioxole
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
ES2576082T3 (es) * 2012-01-31 2016-07-05 Eisai R&D Management Co., Ltd. Derivado de paroxetina
JOP20200225A1 (ar) 2014-08-28 2017-06-16 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT99678B (de) * 1921-09-21 1925-04-10 Hoechst Ag Verfahren zur Darstellung arzneilich wirksamer Quecksilberverbindungen.
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
US5258388A (en) * 1986-03-17 1993-11-02 University Of Florida Anticholinergic compounds, compositions and methods of treatment
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
WO1992009281A2 (en) 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 O,o´−ジアシル酒石酸無水物の製造法
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
JPH08220486A (ja) * 1994-12-14 1996-08-30 Kato Kogei:Kk 眼鏡フレーム
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
MX9707585A (es) * 1995-04-03 1997-12-31 Abbott Lab HOMOGENEOUS MIXTURES OF DRUGS AND FUSION ADDITIVES AT LOW TEMPERATURE FOR CONTROLLED RELEASE.
AU721257B2 (en) * 1995-05-17 2000-06-29 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2234640A1 (en) * 1995-10-31 1997-05-09 Frederick W. Hartner Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
ES2331937T3 (es) * 1996-06-13 2010-01-20 Sumitomo Chemical Company, Limited Derivados de piperidina como intermediarios para la preparacion de paroxetina y procedimiento de preparacion de los mismos.
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
IS1927B (is) 2004-04-15
EP0994872B1 (de) 2001-04-25
US6900327B2 (en) 2005-05-31
TR199903025T2 (xx) 2000-07-21
IL133366A (en) 2005-11-20
NO20033766L (no) 2000-02-09
DK994872T3 (de)
ES2155995T3 (es) 2001-06-01
US5874447A (en) 1999-02-23
SI0994872T1 (de) 2001-08-31
KR100543614B1 (ko) 2006-01-20
CA2293247A1 (en) 1998-12-17
EP1078925A1 (de) 2001-02-28
US7598271B1 (en) 2009-10-06
AT200781T (de) 2001-05-15
CZ429599A3 (cs) 2000-04-12
DE69704679T2 (de) 2001-09-13
CZ295301B6 (cs) 2005-07-13
HK1027352A1 (en) 2001-01-12
US20010031767A1 (en) 2001-10-18
US20090326233A1 (en) 2009-12-31
EE200200633A (et) 2003-02-17
GR3035784T3 (en) 2001-07-31
WO1998056787A1 (de) 1998-12-17
BG103980A (bg) 2000-07-31
CA2293247C (en) 2005-04-12
DE69704679D1 (de) 2001-05-31
AU3108097A (en) 1998-12-30
NO20033765L (no) 2000-02-09
NO995455D0 (no) 1999-11-08
HU0003141A2 (en) 2001-03-28
PT994872E (pt) 2001-09-28
NO20033766D0 (no) 2003-08-25
IL133366D0 (en) 2001-04-30
SK283394B6 (sk) 2003-07-01
HU0003141A3 (en) 2001-04-28
BR9714787A (pt) 2000-07-18
NO995455L (no) 2000-02-09
IS7098A (is) 2004-01-08
EE03970B1 (et) 2003-02-17
JP2002503248A (ja) 2002-01-29
EP0994872B9 (de) 2001-12-05
DK0994872T3 (da) 2001-05-28
NO20033765D0 (no) 2003-08-25
EP0994872A1 (de) 2000-04-26
NO317371B1 (no) 2004-10-18
BG64315B1 (bg) 2004-09-30
EE9900570A (et) 2000-08-15
IS5249A (is) 1999-11-16
PL336895A1 (en) 2000-07-17
KR20010013615A (de) 2001-02-26
SK161999A3 (en) 2000-08-14
PL188450B1 (xx) 2005-02-28
TR200201156T2 (tr) 2002-07-22

Similar Documents

Publication Publication Date Title
DE29724186U1 (de) Injektionsgerät
DE29824544U1 (de) Elektronisches Begrenzungssystem
DE20022618U1 (de) Verbesserte Fußmatte
DE29624402U1 (de) Zahnbürste
DE29724656U1 (de) Befestigungsvorrichtung
DE29924161U1 (de) Implantat
DE29824693U1 (de) Musterbildung
DE29920222U1 (de) Airbag
DE29724428U1 (de) Fußbodenbelag
DE29823590U1 (de) Zahnbürste
DE29822768U1 (de) Verkleidungsmodul
DE29817609U1 (de) Leuchtmittel
DE29912667U1 (de) Fussmatte
DE29624443U1 (de) Steinbohrer
DE29919844U1 (de) Selbstspannfutter
DE29910481U1 (de) Zusammenfaltbare Abdeckung
DE29724281U1 (de) 4-Phenylpiperidin-Verbindungen
DE29924218U1 (de) Gleitschalungsfertiger
DE29908019U1 (de) Schlappen
DE20080003U1 (de) Antrieb
DE29903296U1 (de) Mikroreaktor
DE29824574U1 (de) Strumpf
DE29817529U1 (de) Ausgabeautomat
DE29914730U1 (de) Hefter
DE29823606U1 (de) Umformvorrichtung

Legal Events

Date Code Title Description
R207 Utility model specification

Effective date: 20000914

R150 Utility model maintained after payment of first maintenance fee after three years

Effective date: 20000810

R151 Utility model maintained after payment of second maintenance fee after six years

Effective date: 20030707

R152 Utility model maintained after payment of third maintenance fee after eight years

Effective date: 20050715

R071 Expiry of right